The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
Site Search
Showing 21 - 30 of 123 results
News
|
March 19, 2010
|
1 min read
News
|
Dec. 28, 2007
|
2 min read
News
|
Aug. 7, 2018
|
3 min read
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
News
|
Feb. 12, 2018
|
4 min read
Today, the U.S. Food and Drug Administration approved the use of ivacaftor (Kalydeco®) for children with cystic fibrosis ages 1 to 2 who have at least one mutation that is responsive to ivacaftor.
News
|
Aug. 15, 2018
|
3 min read
Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.
News
|
Aug. 2, 2018
|
2 min read
News
|
Sept. 29, 2006
|
1 min read
Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies
Press Release
|
May 19, 2010
|
3 min read
Press Release
|
Feb. 4, 2008
|
6 min read
News
|
May 17, 2010
|
3 min read